Abstract: The present invention relates to a pharmaceutical formulation in powder form comprising amoxicillin, cineole and a pharmaceutically acceptable oil. The present formulation may also comprise clavulanic acid. It is intended for oral administration, preferably after suspension in an aqueous solvent. The present invention also relates to a combination of cineole and amoxicillin for use in the treatment of an infectious pathology, preferably a bacterial infection, in an individual. The present combination may also comprise a ?-lactamase inhibitor, preferably clavulanic acid. The combination according to the invention makes it possible in particular to combat infections caused by bacteria that are resistant to antibiotics, preferably to antibiotics of the ?-lactamine family.

Abstract: The present invention relates to a pharmaceutical composition. The inventive pharmaceutical composition comprises: at least a first therapeutically-active substance which is selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone and the isomers, derivatives and mixtures thereof; and at least a second therapeutically-active substance which is an antifungal agent.

Abstract: The invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is an antibiotic.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is an antiparasitic agent, in particular, an antimalarial agent. The invention is for use in the field of pharmaceutics.

Abstract: The invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone and beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is antitumoral. The invention is for use in the field of pharmaceutics.

Abstract: The invention concerns a novel method adapted to experimental conditions, for determining the function defining the actual detecting sensitivity of a solid-state detector of nuclear traces and which represents the detecting performances for each type of nucleus emitting energy alpha particles Ei, located in each position inside a sample to be analyzed, and hence precision dosimetry of the radioactive nuclei in a sample using nuclear trace solid-state detectors. The method provides an improvement of the quality of sample analyses, a significant reduction of analysis costs and an important widening of the scope of application of this type of detectors. Thus, the method will bring about the development of a new generation of detectors having a better price-quality ratio which can be found in the field of radioactive nuclei analyses in different types of samples.